Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Volume: 28, Issue: 9, Pages: 2756 - 2767
Published: Apr 11, 2017
Abstract
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administered, selective C5a receptor inhibitor, could replace oral glucocorticoids without compromising efficacy. In this randomized, placebo-controlled trial, adults with newly diagnosed or relapsing...
Paper Details
Title
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Published Date
Apr 11, 2017
Volume
28
Issue
9
Pages
2756 - 2767
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History